--- title: "Incyte: Competitors & Industry Structure" description: "Incyte compared with companies that share its SEC industry classification: revenue, growth and margins from SEC filings, and how the peer group is chosen." canonical: https://www.getswoopr.com/stocks/companies/incyte/competitors/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Incyte: Competitors & Industry Structure ## Direct Answer SEC EDGAR classifies Incyte under SIC code 8731 (Services-Commercial Physical & Biological Research). Among Swoopr's S&P 500 Equal Weight companies, 9 others share that classification; by latest reported revenue, Incyte ranks 2 of 10. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes. ## How Does Incyte Compare With Its Peers? | Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin | | --- | --- | --- | --- | --- | | [IQVIA (IQV)](https://www.getswoopr.com/stocks/companies/iqvia/) | $16.3 billion FY2025 | 5.9% | 13.4% | 8.3% | | **Incyte (INCY)** | $5.1 billion FY2025 | 21.2% | 29.5% | 25.0% | | [Charles River Laboratories (CRL)](https://www.getswoopr.com/stocks/companies/charles-river-laboratories/) | $4.0 billion FY2025 | -0.9% | 0.6% | -3.6% | | [Medpace Holdings Inc. (MEDP)](https://www.getswoopr.com/stocks/companies/medpace-holdings-inc/) | $2.5 billion FY2025 | 20.0% | 21.1% | 17.8% | | [NRC Health (NRC)](https://www.getswoopr.com/stocks/companies/nrc-health/) | $137 million FY2025 | -4.0% | 16.4% | 8.4% | | [MaxCyte Inc. (MXCT)](https://www.getswoopr.com/stocks/companies/maxcyte-inc/) | $33 million FY2025 | -14.5% | -157.1% | -135.1% | | [OmniAb Inc. (OABI)](https://www.getswoopr.com/stocks/companies/omniab-inc/) | $19 million FY2025 | -29.3% | -369.5% | -347.0% | | [bioAffinity Technologies Inc. (BIAF)](https://www.getswoopr.com/stocks/companies/bioaffinity-technologies-inc/) | $6 million FY2025 | -34.2% | -171.6% | -242.0% | | [Absci Corporation (ABSI)](https://www.getswoopr.com/stocks/companies/absci-corporation/) | $3 million FY2025 | -38.2% | -4297.0% | -4113.7% | | [iSpecimen Inc. (ISPC)](https://www.getswoopr.com/stocks/companies/ispecimen-inc/) | $2 million FY2025 | -79.2% | -465.4% | -543.7% | Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care. ![Bar chart of operating margin for Incyte and 7 peers: IQVIA (IQV) 13.4%, Incyte (INCY) 29.5%, Charles River Laboratories (CRL) 0.6%, Medpace Holdings Inc. (MEDP) 21.1%, NRC Health (NRC) 16.4%, MaxCyte Inc. (MXCT) -157.1%, OmniAb Inc. (OABI) -369.5%, bioAffinity Technologies Inc. (BIAF) -171.6%.](https://www.getswoopr.com/images/charts/incyte-competitors-peer-margins.webp) *Operating margin of Incyte against companies sharing its SEC industry classification, from the table above. Select the chart to open it full size.* ## How Does Incyte Rank Among All SEC Filers in Its Industry Code? 10 companies with annual reports in Swoopr's SEC dataset share SIC code 8731 (Services-Commercial Physical & Biological Research), a wider group than the S&P 500 Equal Weight companies above. Ranks run from 1 (highest) and use each company's latest fiscal year, in U.S. dollars. | Measure | Incyte | Median of filers | Rank | | --- | --- | --- | --- | | Revenue | $5.1 billion | $85 million | 2 of 10 | | Revenue growth | 21.2% | -9.2% | 1 of 10 | | Operating margin | 29.5% | -78.3% | 1 of 10 | | Net margin | 25.0% | -69.4% | 1 of 10 | A SIC code reflects the filer's main business as the SEC records it, so the group mixes companies of very different size; the median is a better guide than the average, and a rank near the top by revenue says nothing about quality. ## Where These Numbers Come From Every figure on this page is a value Incyte reported in its own SEC filings, read from the SEC's XBRL data (accession 0000879169-26-000010 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### Who are Incyte's competitors? Companies sharing Incyte's SEC classification (SIC code 8731 (Services-Commercial Physical & Biological Research)) include IQVIA (IQV), Charles River Laboratories (CRL), Medpace Holdings Inc. (MEDP), NRC Health (NRC), MaxCyte Inc. (MXCT). Its 10-K names the competitors it considers most relevant. ### How does Incyte compare with its peers on margins? Incyte's fiscal 2025 operating margin was 29.5%, against a peer median of -157.1%. ### How are these peers chosen? By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict. ### How does Incyte rank among all companies in its SEC industry? Among 10 SEC filers under SIC code 8731, Incyte ranks 2 by latest revenue, and 1 of 10 by operating margin (29.5% against a median of -78.3%). ## References - [SEC EDGAR: INCYTE CORP Form 10-K filed February 10, 2026](https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm) - [SEC EDGAR: INCYTE CORP annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=879169&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [Incyte company dossier](https://www.getswoopr.com/stocks/companies/incyte/) - [Incyte financial metrics](https://www.getswoopr.com/stocks/companies/incyte/metrics/) - [Incyte financial risk indicators](https://www.getswoopr.com/stocks/companies/incyte/risks/) - [Incyte peer comparison](https://www.getswoopr.com/stocks/companies/incyte/competitors/) - [Incyte business model and revenue mix](https://www.getswoopr.com/stocks/companies/incyte/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).